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CMV and EBV are the most ubiquitous herpes viruses, 
with a prevalence of up to 95% for EBV and close to 
50% for CMV in the adult Western population [1]. 
Following primary infection, most often during early 
life, both viruses establish life-long latent infection. 
While immune-competent hosts are mostly asympto-
matic, CMV and EBV can cause illness in immune-
compromised individuals. Importantly, CMV is known 
to significantly shape the immune system with in-
creasing age. Specifically, inflation of CMV-specific 
CD8+ T cells with a terminally differentiated phenotype 
(CD8+CD28–) and an inverted CD4 / CD8 T cell ratio 
have been described in CMV-positive individuals [2, 3].  
 
The OCTO Immune Longitudinal Study established an 
immune risk profile (IRP) – characterized by latent 
CMV infection, inversion of the CD4 / CD8 T cell ratio, 
and accumulation of T cells lacking expression of CD28 
– which was predictive of 2-year mortality in healthy 
donors of more than 80 years of age [4, 5]. Follow-up 
studies over the entire adult life span established that 
these immune changes as well as mortality rates 
associated with the IRP markedly increase in the age 
range of 60-94 years [6]. Recent work extended these 
findings, showing that CMV is a driving force behind 
the IRP [7]. The contribution of EBV to immune-
senescence is far less well studied, not least because the 
high prevalence of EBV-positive individuals among the 
adult population is making detailed studies challenging. 






















Natural  killer  cells  lacking  expression  of  CD56  (CD56neg  NK  cells)  have  been  described  in  chronic  HIV  and
hepatitis C virus infection. Features and functions of CD56neg NK cells in the context of latent infection with CMV
and / or EBV with age are not known. In a cohort of healthy donors >60 years of age, we found that co‐infection





cell  receptor  expression,  and  no  upregulation  of  the  negative  co‐stimulation  receptors  PD‐1  or  TIM‐3 were
observed. In all, our data  identify expansion of dysfunctional CD56neg NK cells  in CMV+EBV+ elderly  individuals
suggesting  that  these  cells  may  function  as  shape‐shifters  of  cellular  immunity  and  argue  for  a  previously
unrecognized role of EBV in mediating immune risk in the elderly. 
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NK cells are group 1 innate lymphoid cells (ILC-1) with 
high cytotoxic activity and an ability to produce large 
amounts of IFN-γ when interacting with infected or 
transformed target cells [8]. Human NK cells can be 
divided into two main populations based on their 
relative expression of the adhesion molecule CD56 and 
the low-affinity Fc receptor CD16 [9, 10]. CD56dim 
(CD56+CD16++) NK cells constitute the majority of NK 
cells in peripheral blood and represent the main effector 
population [9], while CD56bright (CD56++CD16–) cells 
are predominantly found within lymphoid tissues and 
constitute 5-10% of peripheral blood NK cells [11]. 
Developmentally, CD56bright NK cells are thought to be 
precursors of the more differentiated CD56dim NK cell 
subset [12-14]. More recently, a third NK cell subset 
has been described that lacks CD56 expression (CD56–
CD16++; referred to as CD56neg NK cells throughout the 
manuscript) [15-21]. Loss of CD56 expression, in con-
juncture with the lack of an alternative NK cell-specific 
marker in humans, complicates characterization of this 
NK cell subset. Earlier studies identified CD56neg NK 
cells by exclusion of cells expressing CD3, CD4, CD14, 
and CD19 [19, 22-24]. A more recent report further 
established exclusion of cells lacking expression of 
CD7 from the CD3-negative lymphocyte fraction as a 
more reliable means to exclude cells of the myeloid 
lineage (monocytes, dendritic cells) from the NK cell 
population [22, 25, 26]. 
 
Persistent viral infections have a significant impact on 
NK cell phenotype and function [27, 28]. In chronic 
HIV infection, a dramatic increase in CD56neg NK cells 
has been described [15-21]. Compared to CD56dim NK 
cells these cells were shown to be markedly impaired in 
their capacity to secrete IFN-γ, lyse HLA-I-deficient 
target cells, and participate in antibody-dependent 
cytotoxicity (ADCC) [15, 17, 18, 21, 29]. Although less 
pronounced, expansion of CD56neg NK cells was also 
reported in chronic hepatitis C virus (HCV) infection 
[23] and in patients with Burkitt’s lymphoma [30]. 
Similar to HIV-infected individuals, patients with 
chronic HCV infection accumulated CD56neg NK cells 
that were impaired in their capacity to degranulate and 
secrete IFN-γ and TNF-α in response to target cell 
stimulation [23]. It has therefore been hypothesized that 
the expansion of this assumed defective CD56neg NK 
cell population reflects a mechanism by which viruses 
subvert NK cell responses. 
 
Here we performed phenotypic and functional analyses 
of CD56neg NK cells in a cohort of healthy donors of 
>60 years of age (n=38, median 64 years, range 62-70 
years) with known CMV and EBV serostatus. Spe-
cifically, we enumerated CD56neg NK cells and tested 
their cytotoxic capacity in response to target cell and 
cytokine stimulation, determined the differentiation 
stage of CD56neg NK cells relative to other NK cell 
subsets, and assessed cell senescence and exhaustion 
characteristics. 
 
RESULTS AND DISCUSSION 
 
CD56neg NK cells with impaired effector function 
expand in CMV / EBV co-infected hosts >60 years of 
age 
 
The imprint of chronic viral infections on immunity is 
most pronounced during later stages of life. To study 
the impact of CMV infection on NK cell immunity 
during aging we first determined frequencies of NK cell 
subsets in 20 young (<35 years (median 31 years, range 
25-34 years)) and 41 elderly (>60 years (median 64 
years, range 62-70 years)) donors stratified according to 
CMV serostatus. Intriguingly, CMV infection in healthy 
donors >60 years of age was associated with a distinct 
increase in the frequency of CD56neg and a decrease in 
CD56dim NK cells (Figure 1A). In contrast, young 
CMV-positive donors had less CD56bright NK cells but 
an increased proportion of CD56dim cells (Figure 1A). 
No changes in the frequency of CD56neg NK cells were 
seen in young CMV-positive donors (Figure 1A) – in 
line with 2 previous reports [31, 32]. To delineate the 
relative contribution of CMV vs. EBV infection to the 
observed increase in CD56neg NK cells, we next divided 
the cohort of elderly donors into CMV–EBV– (n=11), 
EBV-positive (CMV–EBV+, n=24), CMV-positive 
(CMV+EBV–, n=6) and CMV+EBV+ (n=14) donors 
[33]. NK cells were identified in total PBMCs by gating 
on CD3– and CD7+ positive lymphocytes [26], then 
divided into three subsets based on their CD56 and 
CD16 expression: CD56bright (CD56++CD16–), CD56dim 
(CD56+CD16++), and CD56neg (CD56–CD16++) NK 
cells (Supplementary Figure 1A). When comparing NK 
cell subsets between cohort subgroups stratified 
according to CMV and EBV serostatus, we found a 
significant increase in frequency (Figure 1B, 
Supplementary Figure 1B) and absolute cell numbers 
(Figure 1C) of CD56neg NK cells in CMV+EBV+ 
individuals only, although the low sample number in the 
CMV+EBV– subgroup poses some limitation to this 
conclusion. Expansion of CD56neg NK cells in 
CMV+EBV+ donors was accompanied by a reduction in 
CD56dim NK cell numbers compared to CMV+ donors 
without EBV infection (Figure 1C). 
 
CD56neg NK cells with reduced cytotoxic function have 
been described in chronic HIV and HCV infection [15-
21]. Aiming to investigate effector functions of CD56neg 
NK cells in CMV and EBV co-infected donors, we 
FACS-sorted CD56neg and CD56dim NK cells from all 4 
cohort subgroups stratified according to CMV and EBV 
serostatus as described above. We then assessed 
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expression of CD107a and production of IFN-γ in 
response to stimulation with K562 target cells, IL-12 / 
IL-18 (Figure 1D, F) and the killing capacity toward 
K562 target cells (Figure 1E). We found a significant 




















































compared to CD56dim cells in CMV–EBV– (n=7) and 
CMV+EBV– (n=6) donors, and an even more pro-
nounced decrease in CD107a in CD56neg NK cells 
from CMV+EBV+ (n=5) donors (Figure 1D). Moreover, 























































as  in Supplementary Figure S1A.  (B) Representative FACS dot plots  from a CMV–EBV– and a CMV+EBV+ donor are shown. Numbers
indicate the percentage of cells within total NK cells in peripheral blood. (C) Absolute cell numbers for CD56dim and CD56neg NK cells –
as determined by FACS analysis  in  total PBMCs– are shown  in a cohort of HDs >60 years of age stratified as CMV–EBV–  (n=11/11),
CMV–EBV+ (n=10/24), CMV+EBV– (n=6/6), and CMV+EBV+ (n=12/14). (D‐F) FACS‐sorted CD56dim and CD56neg NK cells from CMV–EBV–
(n=7), CMV–EBV+ (n=4), CMV+EBV‐ (n=4) and CMV+EBV+ (n=5) donors were either left un‐stimulated (empty bars), stimulated with IL‐
12 /  IL‐18 (green bars) or K562 target cells (blue bars) and D) CD107a expression (E) target cell  lysis and (F)  IFN‐γ production were
assessed  after  6 hours of  (co‐)culture. Parametric data were  compared by  Student’s  t‐test  and  are  shown  as mean  ±  SEM, non‐
parametric data by Mann‐Whitney test and are shown as median ± IQR, respectively. * p≤0.05, ** p≤0.005, *** p≤0.005. 
www.aging‐us.com  727  AGING 
creased in response to both target cell and cytokine 
stimulation in the CD56neg cell subset (Figure 1D). We 
then tested killing capacity of sorted CD56dim and 
CD56neg NK cells from all 4 cohort subgroups by 
measuring lysis of K562 target cells, a more direct 
measure of cytotoxic capacity. In co-culture with K562 
target cells, CD56neg NK cells from CMV+EBV– and 
CMV+EBV+ donors had a significantly lower killing 
capacity than CD56dim NK cells from the same donor 
(Figure 1E). Analogous to the expression of CD107a, 
production of IFN-γ was significantly lower in CD56neg 
as compared to CD56dim NK cells in CMV–EBV+(n=4), 
CMV+EBV– (n=5) and CMV+EBV+ (n=5) donors after 
stimulation with K562 target cells (Figure 1F). In 
response to IL-12 / IL-18 stimulation, only CMV+EBV+ 
donors showed a significant reduction in IFN-γ 
production (Figure 1F). Intriguingly, CD56dim NK cells 
from CMV-positive donors had a significantly higher 
capacity to secrete IFN-γ than those from CMV-
negative individuals (Figure 1F). These data are in line 
with previous reports that established a role for CMV in 
shaping immune reactivity of CD56dim NK cells both in 
vitro and in vivo [34, 35], a phenomenon that was not 
recapitulated in the CD56neg NK cell subset (Figure 1F). 
In all, our data suggested that CD56neg NK cells had 
reduced cytotoxic capacity and IFN-γ production 
compared to CD56dim NK cells, a feature that was 
further pronounced in the context of CMV / EBV co-
infection. 
 
Frequencies of CD56neg NK cells in donors >60 years 
of age correlate with the immune risk profile 
 
CMV infection has been associated with significant 
changes in T cell subset distribution with age. 
Population-based studies, pioneered by the Swedish 
longitudinal OCTO immune study, established an 
immune risk profile (IRP) characterized by CMV 
positivity, an inversed CD4 / CD8 T cell ratio and 
accumulation of end-differentiated T cells with poor 
proliferative capacity – an immunologic imprint that has 
been associated with a higher 2-year-mortaliity rate in 
healthy donors >60 years of age [6]. We next analyzed 
whether an increase in CD56neg NK cells may be 
associated with the IRP. To this end, we performed 
phenotypic analysis of CD4+ and CD8+ T cells 
classified as naïve (N; CD27+, CD45RA+), central 
memory (CM; CD27+, CD45RA–), effector memory 
(EM; CD27–, CD45RA–) and terminally-differentiated 
effector memory (EMRA; CD27–, CD45RA+) T cells, 
and determined the number of double negative (DN; 
CD27–CD28–) T cells [36, 37] in all 4 subgroups of the 
cohort (Supplementary Figure S1A). Indeed, fre-
quencies of CD56neg NK cells correlated with the 
percentage of end-differentiated T cells, specifically 
CD8+ EMRA and CD27–CD28– T cells, and a reduced 
CD4 / CD8 T cell ratio (Figure 2A). When stratified to 
CMV and EBV serostatus, only donors that were either 
CMV- or EBV-positive (or both) showed a positive 
correlation between the frequency of CD56neg NK and 
CD8+ EMRA T cells (Supplementary Figure S2A, left 
panel). 
 
This newly identified association of CD56neg NK cells 
with the IRP raised the question whether CD56neg NK 
cells are a terminally-differentiated subset as well, and 
whether they display cell senescence characteristics. To 
determine the differentiation stage of CD56neg NK cells 
we analyzed cell surface expression of NKG2A, 
CD62L, the Killer-cell Immunoglobulin-like Receptors 
(KIRs), and CD57. Expression of NKG2A and CD62L 
in NK cells is reciprocal to KIR and CD57 expression, 
with a step-wise reduction in NKG2A and CD62L and 
progressive acquisition of KIR and CD57 with 
differentiation [38, 39]. In our cohort, CD56neg NK cells 
displayed a decrease in NKG2A and CD62L expression 
and acquisition of KIR and CD57 compared to 
CD56bright NK cells irrespective of the serostatus of the 
donors (Figure 2B and Supplementary Figure S2B), 
suggesting that CD56neg cells have a mature phenotype. 
Compared to CD56dim NK cells, however, CD56neg NK 
cells expressed significantly less KIR and CD57 (Figure 
2B and Supplementary Figure S2B). CD57 expression 
defines mature NK cells with potent effector function 
[40], and acquisition of KIR is associated with 
‘licensing’ of the NK cell (a process in which only cells 
that express KIR for self-MHC molecules acquire 
maximal functional capacity [41]). Absence of these 
two markers could point to either a more immature cell 
subset that has not acquired full effector functions, or a 
cell subset with faulty licensing, respectively, which 
would be in line with their reduced effector functions as 
shown in Figure 1D-F. 
 
Having established that CD56neg NK cells have a mature 
phenotype, we next investigated whether they acquire 
cell senescence characteristics. Loss of proliferative 
capacity is a hallmark of cell senescence. Therefore, we 
first assessed proliferation of NK cell subsets directly ex 
vivo, by staining for Ki-67, expression of which is 
found in cycling cells only. CD56neg NK cells had 
intermediate levels of Ki-67 expression compared to 
CD56bright and CD56dim NK cells, recapitulating our 
phenotyping results in Figure 2B, that established an 
intermediate differentiation phenotype for the CD56neg 
NK cell subset. Intriguingly, we observed reduced Ki-
67 expression in all three NK cell subsets in 
CMV+EBV+ donors when compared to CMV–EBV– 
individuals and this reduction was most pronounced in 
CD56bright NK cells (Figure 2C). There was no sig-
nificant difference in Ki-67 expression between CMV–
EBV–   and   single   positive   (CMV–EBV+   and   CMV+ 





















































































































value)  are  indicated  for  each  scatter plot.  (B)  The differentiation  stage of CD56neg NK  cells was assessed by  FACS  analysis  for
NKG2A, CD62L, KIR and CD57 expression in total PBMCs. CD56neg NK cells were compared to CD56bright and CD56dim NK cells from



















EBV–) donors (Supplementary Figure 2C). In senescent 
cells, the defect in proliferative capacity is occasionally 
associated with telomere erosion. To test whether 
CD56neg NK cells display telomere-dependent senes-
cence, we measured telomere length by flow-cytometry 
based fluorescence in situ hybridization (FISH)-method. 
CD56neg NK cells displayed intermediate telomere 
length compared to CD56bright and CD56dim NK cells, 
excluding critical telomere shortening in CD56neg NK 
cells as an explanation for the low Ki-67 levels (Figure 
2D). Interestingly, telomere shortening was associated 
with CMV and EBV co-infection in more immature cell 
subsets such as CD56bright NK cells (Figure 2D) and 
naïve CD8+ T cells (Supplementary Figure 2D). 
Alternatively, cell senescence can be induced by DNA 
damage such as DNA double strand breaks (DSBs), 
which are marked by phosphorylation of histone 2A.X 
(γH2A.X) and that elicit DNA repair mechanisms 
collectively termed as DNA damage response (DDR). 
Similar to telomere-associated replicative senescence, 
stress-induced and age-associated senescence leads to 
the formation of DNA-damage foci and activation of the 
DDR [42]. To test for DDR activation in CD56neg NK 
cells we first probed global phosphorylation of H2A.X 
and spontaneous activation of p38 mitogen-activated 
protein kinase (MAPK) [43, 44] in CD56neg and 
CD56dim NK cells by FACS. Interestingly, H2A.X 
phosphorylation (Figure 2E, F) and p-p38 MAPK levels 
(Figure 2G) were lower in CD56neg compared to 
CD56dim NK cells (Figure 2G) and no significant effect 
of CMV and EBV co-infection was seen on H2A.X and 
p38 phosphorylation (Figure 2E-G). In a recent report 
from Hewitt et al., persistent DNA damage foci, that 
failed to be resolved by the DDR,  mapped to telomeres/ 
telomere associated structures rather than genomic 
DNA, presumably because of the inaccessibility of 
telomeres to the DDR machinery [42]. Such persistent 



















γH2A.X with telomeres in a fluorescence in situ 
hybridization protocol and reliably identified senescent 
fibroblasts [42]. To further corroborate our findings of 
telomere-independent senescence, we applied this 
immune-FISH procedure on sorted CD56neg and 
CD56dim NK cells from all four subgroups of the cohort 
(n=3 each). Telomere-associated fluorescence (TAF) 
was defined as co-localization of γH2A.X with the telo-
mere probe (Figure 2H). We found that the frequency of 
TAF-positive cells was strongly donor-dependent, 
ranging from 11 to 38% of NK cells, and it showed no 
clear association with CMV and EBV serostatus (Figure 
2J and Supplementary Figure 2E, upper panels). There 
was no difference in the frequency of TAF-positive 
cells between CD56neg and CD56dim NK cells (18.2% vs 
19.6% (mean TAF+ cells CD56neg vs CD56dim). 
Likewise, the number of TAF foci / TAF+ cell was not 
different between the groups (Figure 2J and Supple-
mentary Figure 2E, bottom panels). Taken together, our 
data argue against a senescent phenotype in CD56neg 
NK cells. 
 
CD56neg NK cells lack features of exhausted cells 
 
Exhausted NK cells have been described in chronic 
HIV, CMV and hepatitis B and C virus infection, and in 
human and animal cancers. Common characteristics of 
exhausted NK cells are impaired cytotoxicity and 
cytokine secretion, down-regulation of activating NK 
cell receptors and upregulation of inhibitory receptors, 
such as TIM-3 and PD-1. The transcription factors 
Eomesodermin (Eomes) and T-box transcription factor 
(T-bet) are modulated during maturation of NK cells, 
with progressive T-bet upregulation and Eomes down-
regulation toward terminal differentiation [45]. Gill et 
al. described reduced expression of Eomes and T-bet as 
a molecular signature of exhausted NK cells in an 
animal model of lymphoma [46].  To  test  if  expanding  
CMV–EBV–  (gray bars, n=10/11) and CMV+EBV+ donors  (black bars, n=10/14).  (C) Proliferation of NK cell subsets  from CMV–EBV–
(gray bars, n=10/11) and CMV+EBV+ (black bars, n=10/14) donors as assessed directly ex vivo by FACS analysis for Ki‐67 expression.
(D) Telomere length of NK cell subsets in CMV–EBV– (gray bars, n=10/10) and CMV+EBV+ donors (black bars, n=10/14) as assessed by
FACS‐based  FISH‐technique. Data  are  shown  as  geometric mean of  fluorescence  intensity  (gMFI) of  the  telomere probe  (TelC),
normalized to the gMFI TelC value of the total  lymphocyte population  for each donor.  (E) Global phosphorylation of the histone
H2A.X (γH2A.X Ser139) in CD56dim and CD56neg NK cells in CMV–EBV– (gray bars, n=8/11) and CMV+EBV+ donors (black bars, n=9/14)
as assessed directly ex vivo by FACS analysis. (F) Representative histograms for γH2A.X staining in a CMV–EBV– (gray histograms) and
CMV+EBV+  (blue  histograms)  donor.  UV‐irradiated  PBMCs  served  as  positive  control.  (G)  Phosphorylation  of  p38‐MAPK




stack  images of the telomere probe (bottom  left) and γH2A.X foci are shown  (bottom right). (J) Cumulative data from CMV–EBV–
(gray bars, n=3) and CMV+EBV+ (black bars, n=3) donors are shown analyzed as in (H). Top panel shows the frequency of TAF+ cells,
bottom panel the number of TAF / TAF+ cell in CD56dim and CD56neg NK cells. (A‐G) Experiments were performed on total PBMCs.
(H,  J)  Experiments were  performed  on  FACS‐sorted  CD56dim  and  CD56neg NK  cells.  For  parametric  data mean  ±  SEM,  for  non‐
parametric data median ± IQR are shown. * p≤0.05, ** p≤0.005, *** p≤0.005, **** p≤0.0005, ns=not significant. 

















































































































Figure 3. CD56neg NK cells  lack  features of exhausted cells.  (A) Overlay contour plot analysis comparing T‐bet and Eomes








NK cells were either  left un‐stimulated  (empty bars),  stimulated with K562 cells alone  (green bars) or K562 cells and a blocking
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CD56neg NK cells in CMV+EBV+ donors have features 
of exhausted cells, we first assessed expression of T-bet 
and Eomes in CD56neg NK cells within all 4 subgroups 
of the cohort and compared them to CD56dim NK cells. 
We found reduced T-bet expression in CMV+EBV+ 
individuals compared to CMV–EBV– donors for both 
NK cell subsets (Figure 3A). This was exemplified by 
an increase in cells expressing low levels of T-bet (T-
betlo) and a decrease in cells with high T-bet expression 
(T-bethi) (Figure 3B, upper panel). Eomes expression 
tended to be lower in CMV+EBV+ compared to CMV–
EBV– donors (Figure 3B, lower panel). CMV single 
positive (CMV+EBV–) donors showed a similar trend in 
T-bet and Eomes modulation as CMV+EBV+ donors 
(Supplementary Figure S3A), suggesting that changes 
in T-bet and Eomes expression are associated with 
CMV infection and are further enhanced by EBV co-
infection. Nonetheless, differences in T-bet and Eomes 
expression between CD56dim and CD56neg NK cells 
were tenuous and cannot account for the reduced 
effector functions seen in CD56neg NK cells. 
 
Expression of the immune check-point inhibitors PD-1 
and TIM-3 have been reported on NK cells in HIV and 
HCV infection as well as various tumor models, and 
blockade of each receptor alone, or in combination, was 
shown to reverse NK cell exhaustion [47-49]. We 
therefore tested for the expression of PD-1 and TIM-3 
within all 4 subgroups of our cohort. There was no 
difference in PD-1and TIM-3 expression between 
CD56dim and CD56neg NK cells irrespective of the 
serostatus of the donor (Figure 3C). We next performed 
phenotypic analyses for the activating NK cell receptors 
NKG2C, NKG2D, and the natural cytotoxicity receptors 
(NCRs) NKp30, NKp44 and NKp46. The association of 
the activating NK cell receptor NKG2C with CMV is 
well established. Correspondingly, we found increased 
levels of NKG2C on both NK cell subsets with CMV 
infection that were further increased by EBV co-
infection (Figure 3D and Supplementary Figure S3B). 
There was no significant difference in NKG2C 
expression between CD56dim and CD56neg NK cells 
(Figure 3D and Supplementary Figure S3B). In contrast, 
expression of the natural cytotoxicity receptor NKp30 
was reduced with CMV and EBV co-infection on both 
NK cell subsets (Figure 3D and Supplementary Figure 
S3B). Further, CD56neg NK cells had higher levels of 
NKp44 expression than CD56dim NK cells irrespective 
of the serostatus of the donors (Figure 3D and Sup-
plementary Figure S3B). In circulation, NKp44 is found 
on activated NK cells only, and engagement of the 
receptor by activating ligands mediates release of cyto-
toxic granules, IFN-γ and TNF-α. In contrast to other 
NCRs, NKp44 is endowed with an inhibitory function 
as well, and it has been postulated that tumors exploit 
this axis to escape NK cell attack [50, 51]. Therefore, 
we next blocked NKp44 with a monoclonal antibody on 
sorted CD56dim and CD56neg NK cells, or an isotype 
control, respectively, and tested expression of CD107a, 
and IFN-γ production in response to K562 target cells as 
well as lysis of K562 target cells. While both CD56dim 
and CD56neg NK cells readily increased CD107a and 
IFN-γ expression after target cell stimulation, no effect 
on effector functions was seen with NKp44 blockade or 
the isotype control (Figure 3E) arguing against a role 




In a cohort of healthy donors >60 years of age, we show 
that CD56neg NK cells expanded in CMV / EBV co-
infection and that their frequency correlated with the 
immune risk profile (IRP). CD56neg NK cells were less 
functional when compared to CD56dim cells of the same 
donor in terms of their degranulation, killing capacity 
and IFN-γ production when stimulated with K562 target 
cells or IL-12 / IL-18, a feature that was more pro-
nounced in CD56neg NK cells from CMV+EBV+ donors. 
Phenotypically CD56neg NK cells were mature cells, yet 
compared to CD56dim NK cells they were characterized 
by a CD57lowKIRlow phenotype, reduced T-bet expres-
sion and had longer telomeres compared to CD56dim NK 
cells. CD56neg NK cells thus distinguished themselves 
from CD56dim cells, the main effector population, as a 
distinct cell subset. Neither reduced expression of 
activating NK cell receptors, nor increased expression 
of PD-1 and TIM-3 accounted for reduced functionality 
of CD56neg NK cells. Likewise, no cell senescence 
characteristics were detected in this cell subset. In all, 
our data suggest that CD56neg NK cells can be viewed 
as an additional marker of immune risk in the aging 
host, and that EBV has a previously unrecognized role 
in immune senescence. 
 
MATERIALS AND METHODS 
 
Blood sample collection and assessment of donor 
CMV and EBV serostatus 
 
The cohort of elderly donors (>60 years (median 64 
years, range 62-70 years)) was recruited at the 
University Hospital Basel, Blood Transfusion Centre of 
both Basel, Switzerland. After written informed consent 
was obtained, healthy blood donors aged >60 years who 
routinely presented at the center were assessed for their 
serological EBV status by multiplex microparticle 
technology (Luminex 200 Technology, Luminex, 
Austin, TX, USA). Specifically, we probed for IgG 
antibodies specific for the EBV antigens VCA, EBNA-1 
and EA (EBV-IgG Plus Test, AtheNA Multi-Lyte, 
Inverness Medical, Princeton, NJ, USA). We recruited 
17 EBV-negative individuals and 38 EBV-positive age- 
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and sex-matched controls for a second blood donation 
where buffy coats were obtained. At the recall blood 
donation, EBV serology was repeated for all EBV-
negative donors with multiplex microparticle tech-
nology. CMV serostatus was recorded from previous 
donations for CMV-positive donors or assessed in 
serum or plasma at the time of the recall donation (if 
previously not tested or CMV-negative) utilizing CMV 
lysate-coated microparticles (strain AD169) for the 
capture of human anti-CMV IgG (ARCHITECT CMV 
IgG Assay, Abbott, Baar, Switzerland). Samples from 
this cohort were used for all experiments of this study 
except in Figure 1A, left panel, where the young control 
cohort was used.  
 
20 young donors (<35 years (median 31 years, range 
25-34 years)) who were recruited at the University 
College London after approval of the Local Research 
Ethics Committee of the Royal Free and the University 
College London Medical School, served as a control 
cohort. After informed consent was obtained, whole 
blood was collected in standard heparinized tubes and 
PBMCs were isolated using Ficoll Histopaque 
(Amersham Biosciences). CMV status was obtained as 
described in [52]. Briefly, PBMC were stimulated with 
CMV viral lysate overnight and CMV status was 
obtained by flowcytometry-based assessment of IFN-γ 
production in CD4+ T cells. Previous data from our 
group had shown good concordance between IFN-γ 
responses and CMV IgG serology as obtained from the 
diagnostic laboratory of University College London 
[52].  
 
Cell isolation and sorting of NK cells 
 
PBMCs were isolated from buffy coat preparations by 
standard Lymphoprep (STEMCELL Biotechnology) 
gradient centrifugation and stored in fetal calf serum 
(FCS) 10% DMSO in liquid nitrogen. NK cells were 
pre-sorted from frozen PBMCs samples by magnetic 
bead isolation using the NK Cell Isolation Kit (MACS 
Technology, Miltenyi Biotec) or the NK Cell 
Enrichment Kit (EasySepTM from STEMCELL 
Biotechnology). Enriched NK cells were then stained 
with anti-CD3 (UCHT1), anti-CD7 (M-T701), anti-
CD56 (HCD56), and anti-CD16 (3G8) (all from 
BioLegend) and CD56dim and CD56neg NK cells were 
sorted on a FACSAria (BD Biosciences) cell sorter. 
Sorted cells were cultured in complete medium (RPMI 
1640 supplemented with 10% heat-inactivated FCS, 
100 U/ml Penicillin, 100 mg/ml Streptomycin, and 2 
mM L-glutamine; all from Invitrogen) at 37°C for 2h 
prior to the functional assays. Sorted NKs were used in 
Figure 1D, 1E, 1F; Figure 2H, 2J; Figure 3E; Figure 




The following antibodies (all from BioLegend unless 
otherwise indicated) were used: anti-CD3 (OKT3), anti-
CD56 (HCD56), anti-CD16 (3G8), anti-CD7 (M-T701), 
anti-CD4 (A161A1), anti-CD8 (RPA-T8), anti-CD27 
(LG.3A10), anti-CD28 (CD28.A), anti-CD45RA 
(HI100), anti-TIM3 (F38-2F2), anti-PD-1 (EH12.2H7), 
anti-CD158e1 (DX9), anti-CD158b (DX27), anti-
CD158f (URR 1), CD158 (HP-MA4) anti-T-bet (4B10), 
anti-Eomes (WD1928, EBioscience), anti-NKG2A 
(131411, R&D Systems), anti-NKG2C (134591, R&D 
Systems), anti NKG2D (149810, R&D Systems), anti-
NKp30 (Z25, Beckman Coulter Diagnostics), anti-
NKp44 (44.189, eBioscience), anti-NKp46 (9E2), Ki67 
(B56, BD Biosciences). A fixable live – dead cell stain 
(UV Zombie, BioLegend) was used to exclude dead 
cells throughout. Biotin-conjugated antibodies were 
detected using Cy5- or Cy3-conjugated Streptavidin 
(BioLegend). T-bet, Eomes and Ki-67 staining was 
performed with the Foxp3 Staining Set (Miltenyi 
Biotec) according to the manufacturer’s instructions. 
All samples were acquired on a LSRFortessa flow 
cytometer (BD Biosciences). Data were analyzed using 




After cell surface staining as defined above cells were 
fixed with PBS 2% paraformaldehyde (PFA) for 10min 
at 37°C and permeabilized with ice-cold Perm Buffer III 
(BD Biosciences). Cells were either stored in Perm 
Buffer III at -20°C or stained immediately with the 
following antibodies for 30 min at room temperature: 
anti-γH2A.X-APC (20E3, BioLegend), anti-p-p38 
MAPK (pT180/pY182)-PE (36/p38, BD Biosciences). 
Samples were acquired immediately after the staining 
on a LSRFortessa flow cytometer (BD Biosciences). 
Data were analyzed using FlowJo®_V10.4 software 
(Tree Star, Ashland, OR). 
 
Multi-color flow-FISH analysis of telomere length 
 
Relative telomere length of NK and T cell subsets was 
assessed as previously described [53]. Briefly, PBMCs 
were first stained with a biotinylated anti-CD28 
(CD28.A) antibody, followed by Streptavidin-
conjugated-Cy3, a fixable live – dead cell stain (UV 
Zombie, BioLegend) and anti-CD56 (HCD56), anti-
CD7 (M-T701), anti-CD3 (OKT3), anti-CD4 
(A161A1), anti-CD8 (RPA-T8), anti-CD16 (3G8), anti-
CD45RA (HI100), anti-CD27 (LG.3A10). Samples 
were then washed in PBS, fixed with 1 mM BS3 
(Thermo Scientific UK) and quenched with 50 mM 
Tris–HCl in PBS (pH 7 2, 20 min, room temperature). 
For the hybridization step, cells were resuspended in 
www.aging‐us.com  733  AGING 
70% deionized formamide, 2.85 mM Tris–HCl pH 7.2, 
1.4% BSA and 0.2 M NaCl and 0.75 μg/ml of PNA 
TelC-Cy5 probe (PNA Bio, US) was added. Samples 
were then heated for 10 min at 82°C before being 
rapidly cooled down on ice. After 1 hour of incubation 
at room temperature, samples were washed twice in 
70% deionized formamide, 14.25 mM Tris–HCl pH 7.2, 
0.14% BSA, 0.2 M NaCl, 0.14% Tween-20 in 2% 
BSA/PBS twice before acquisition on a LSRFortessa 
cytometer (BD Biosciences). Quantum Cy5 molecules 
of Equivalent Soluble Fluorochrome (MESF) beads 
(Bangs Laboratories, USA) were acquired alongside 
samples in each experiment to ensure standardization of 
FACS machine set up. Data were analyzed using 
FlowJo®_V10.4 software (Tree Star, Ashland, OR). 
 
CD107a and IFN-γ assay in sorted NK cells 
 
Flow-sorted CD56dim and CD56neg NK cells were 
cultured in complete medium at 37°C for 2 hours prior 
to stimulation. 100’000 NK cells / well were seeded in 
96-well U-bottom plates and activated either with IL-12 
(10 ng / μl) and IL-18 (50 ng / μl) or with K562 target 
cells at an effector-to-target ratio of 5:1 in complete 
medium. Brefeldin A, Monensin and an anti-CD107a 
antibody (BD Biosciences) were added after 30 minutes 
of culture. NK cells were then harvested after 6 hours of 
activation / co-culture and fixed in Fixation / Per-
meabilization solution (BD Bioscience) for 15 minutes 
at room temperature. For the detection of intracellular 
IFN-γ, samples were stained with an anti-IFN-γ 
antibody (B27, Immunotools) in Perm/Wash buffer (BD 
Biosciences) for 30 min at room tempe-rature. All 
samples were acquired immediately after the staining on 
a LSRFortessa flow cytometer (BD Bio-sciences). Data 
were analyzed using FlowJo®_V10.4 software (Tree 




Flow-sorted CD56dim and CD56neg NK cells were 
cultured in complete medium at 37°C for 2 hours prior 
to stimulation. 100’000 NK cells were seeded in 96-
well U-bottom plates and stimulated with K562 target 
cells labeled with Cell Proliferation Dye eFluor670 
(ThermoFisher) at an effector-to-target ratio of 5:1 in 
complete medium. To control for spontaneous cell 
death, labeled target cells were plated in the absence of 
effector cells. After 4 hours of incubation, cells were 
stained with Zombie Green viability dye (BioLegend) 
and analyzed by FACS. % specific lysis was calculated 
as (% dead target cells in experimental condition - % 
dead target cells in control) / (100% - % dead target 
cells in control) x 100. 
 
Telomere fluorescence in situ hybridization 
 
Flow-sorted CD56dim and CD56neg NK cells were 
cytocentrifuged onto poly-L-lysine coated glass slides 
(Cytospin, Thermo Scientific). Staining for telomere-
associated γH2A.X foci (TAF) was then performed as 
previously described [42]. Slides were air dried prior to 
hybridisation with 40 pM PNA probe targeting the TelC 
telomeric repeat (Panagene, TelC Cy3, #14 1224PL-01) 
for 2 hours. Sections were then counter stained for 
γH2A.X (Ser139, Cell Signaling #9718), followed by 
incubation with biotinylated secondary antibody (BA-
1000, Vector) and FITC-streptavidin (A-2011). Slides 
were subsequently washed in formamide/SSC buffer 
prior to mounting with Vectorshield/DAPI (Vector 
Laboratories). Imaging was performed using a Leica 
SPE2 confocal microscope (Leica Microsystem). 





GraphPad Prism software was used to perform all 
statistical analyses. For parametric data Student’s t-test 
or repeated measures ANOVA test with Greenhouse-
Geisser correction were used. For non-parametric data 
Wilcoxon matched-pairs signed rank test or Friedman 





CMV: Cytomegalovirus; DDR: DNA damage response; 
DMSO = Dimethyl sulfoxide; DSB: DNA double strand 
break; EBV: Epstein-Barr virus; Eomes: Eomesodermin; 
FACS: Fluorescence-activated cell sorting; FCS: Fetal 
calf serum; gMFI = Geometric mean; fluorescence 
intensity; HD: Healthy donor; IFN-γ: Interferon-
gamma;  ILC:Innate lymphoid cell; IRP: Immune risk 
profile; KIR: Killer-cell immunoglobulin-like receptor; 
NCR: Natural cytotoxicity receptor; PBMCs: Peripheral 
blood mononuclear cells; TAF: Telomere-associated 
fluorescence; T-bet: T-box transcription factor; TNF-α: 
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performed  by  plotting  FSC‐area  (FSC‐A)  versus  FSC‐height  (FSC‐H)  and  excluding  cells with  disproportionate  cell  size  as






CD27 and CD28 gating  (9 and 11).  (B) Frequencies of CD56bright, CD56dim and CD56neg NK  cells – as determined by FACS
analysis  in  total  PBMCs–  are  shown  in  a  cohort  of HDs  >60  years  of  age  stratified  as  CMV–EBV–  (n=11/11),  CMV–EBV+
(n=21/24), CMV+EBV– (n=6/6), and CMV+EBV+ (n=12/14). * p≤0.05, ** p≤0.005, *** p≤0.005, **** p≤0.0005.  



























































































































































































n=11/12), CMV–EBV+  (green bars, n=9/24), CMV+EBV–  (blue bars, n=6/6) and CMV+EBV+  (red bars, n=11/14) donors within CD56dim
and CD56neg NK cell subsets. To test for an effect of CMV and EBV infection we compared T‐bet and Eomes expression of each cohort
subgroup  and within  each  cell  subset.  (B)  Cell  surface  expression  of  activating NK  cell  receptors NKG2C  and NKG2D  and  natural
cytotoxicity receptors NKp30, NKp44 and NKp46 in CMV–EBV– (gray bars, n=11/11), CMV–EBV+ (green bars, n=9/24), CMV+EBV– (blue
bars, n=6/6) and CMV+EBV+ (red bars, n=11/14) donors within CD56dim and CD56neg NK cell subsets. To test for an effect of CMV and
EBV infection we compared expression of activating NK cell receptors and NCRs within each cohort subgroup and for each cell subset.
All experiments were performed on total PBMCs. For parametric data mean ± SEM, for non‐parametric data median ± IQR are shown.
Data were analyzed by Student’s t‐test and Mann‐Whitney test, respectively. * p≤0.05, ** p≤0.005, *** p≤0.005, ns=not significant. 
 
 
